Pablo Miguel
Barreiro Garcia
Hospital Universitario de Valme
Sevilla, EspañaPublications in collaboration with researchers from Hospital Universitario de Valme (22)
2016
2015
-
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2014
-
Association of low-density lipoprotein receptor genotypes with hepatitis C viral load
Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy
Journal of Infection, Vol. 68, Núm. 4, pp. 372-377
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2013
-
Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin
Clinical Infectious Diseases, Vol. 57, Núm. 3, pp. 465-468
-
Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435
-
Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response
Journal of Infection, Vol. 67, Núm. 1, pp. 59-64
-
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection
AIDS, Vol. 27, Núm. 17, pp. 2715-2724
2012
-
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial
Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968
-
Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123
2011
-
Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
HIV Medicine, Vol. 12, Núm. 8, pp. 487-493
-
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse
AIDS, Vol. 25, Núm. 8, pp. 1131-1133
-
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C
Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295
-
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
Journal of Infectious Diseases, Vol. 203, Núm. 11, pp. 1629-1636
2010
-
Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV
Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216
2009
-
Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation
Antiviral Therapy, Vol. 14, Núm. 2, pp. 187-193
2008
-
Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients
Journal of Hepatology, Vol. 49, Núm. 6, pp. 916-922